ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1902

Structural Severity in Knee Osteoarthritis Impacts Treatment Response: A Post Hoc Pooled Analysis of Lorecivivint Clinical Trials
Abstract Number: 2207

Structural Ultrasound Features of Joints and Tendons of Healthy Children: Development of Normative Data
Abstract Number: 0108

Study of the Level of Antibody Response to COVID-19 Vaccine in a Minority Population with Rheumatological Disorders
Abstract Number: 1410

Subclinical Atherosclerosis Is Not Related with Acid Uric in Rheumatoid Arthritis: Study of 1005 Patients of a Single University Hospital
Abstract Number: 1856

Subclinical Coronary Artery Disease in Patients with Idiopathic Inflammatory Myopathies: A Cross-Sectional Study Evaluation by Computer Tomography Coronary Angiogram
Abstract Number: 1216

Subclinical Vascular Disease Is More Prevalent in above-30 Adult Fibromyalgia: A Preliminary Report of a Hospital-based Cross-sectional Study from South India
Abstract Number: 0643

Subsetting SLE Patients Based on DNA Methylation at the Time of Disease Flare
Abstract Number: 1800

Successful Establishment of Chronic Gouty Arthritis Model in C57BL/6 Mice
Abstract Number: 1369

Sun Protection Use in Patients Followed in a Pediatric Rheumatology Clinic in an Urban Setting
Abstract Number: 1681

Supernatants from Activated Macrophages Contain Citrullinated Vimentin and Induce Extracellular Matrix Deposition from Fibroblasts
Abstract Number: 0105

Supplemental Primary Dose of the COVID-19 Vaccine in Immunosuppressed Patients on DMARDs and Biologic Agents
Abstract Number: 2079

Survey to Prioritize and Generate Domains in Preparation to Update the OMERACT Core Domain Set for Systemic Lupus Erythematosus
Abstract Number: 0941

Surveying Adolescents with Rheumatic Disease for At-Risk Behavior
Abstract Number: 0603

Survivin-dependent Regulation of Bivalent Chromatin and Its Relevance for Adaptive Immunity
Abstract Number: 0790

Sustainability of Immunogenicity of BNT162b2 Vaccine in Patients with Autoimmune Rheumatic Disease, a Retrospective Comparative Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].